Psilocybin therapy is on the verge of becoming the first classic psychedelic approved by the FDA for medical use in the United States, with a regulatory decision possible as early as late 2026 or early 2027. Yet behind the momentum of positive clinical trials and landmark FDA guidance lies a sobering reality: the healthcare system may not be ready to deliver this treatment responsibly at scale.

Compass Pathways recently announced that 39% of nearly 600 patients with treatment-resistant depression showed meaningful clinical response after one to two doses of COMP360, a psilocybin-assisted therapy, with benefits sustained at six months. The company plans to complete its FDA filing in the fourth quarter of 2026, and with a priority review voucher, approval could arrive within one to two months of submission. If COMP360 clears regulatory review, psilocybin would simultaneously be rescheduled off Schedule I, the most restrictive drug classification.

Why Is FDA Approval Not Enough?

The FDA's final guidance for psychedelic clinical investigations, published alongside Compass's trial results, signals genuine regulatory seriousness about this field. However, the guidance also raises the bar significantly higher than many sponsors anticipated. The agency now describes a blinded twelve-month follow-up with prespecified retreatment criteria as "the most informative" trial design, a materially higher evidentiary standard than earlier drafts suggested. Safety packages must now include driving studies, and the guidance explicitly closes the door on sponsors claiming ignorance about expected adverse events.

These are not minor refinements. They reflect an FDA that watched the MDMA-assisted therapy application collapse in 2024 and recalibrated its expectations accordingly. Of the 225 public comments submitted during the draft period, most remained unaddressed in the final document. Sponsors had pushed back on monitor-to-patient ratios, on restrictions against dosing session monitors participating in post-session therapy, and on the length of required follow-up periods. The agency held its position on all three.

What's the Infrastructure Problem?

The real bottleneck is not the molecule itself. It is the clinic. Psilocybin therapy requires approximately four dosing sessions per year, with six-hour monitored sessions per patient, generating roughly 24 hours of clinical chair time per patient annually. By comparison, esketamine (Spravato), a ketamine-based therapy already approved and generating over $2 billion in annual revenue, requires two-hour sessions dosed approximately weekly, producing close to 104 hours of monitored time per patient per year.

Despite years of commercial availability and no direct competitor, only 5% of treatment-resistant depression patients are currently on esketamine. Experts do not expect that figure to exceed 10% even a decade from now, as infrastructure catches up. This suggests that psilocybin approval, while historically significant, will not automatically translate into widespread access. The system that struggles to deliver esketamine to 10% of eligible patients will face even greater challenges scaling a therapy that requires longer, more intensive monitoring sessions.

How to Prepare for Psychedelic Therapy Expansion

• Regulatory Clarity: The FDA's final guidance establishes specific requirements for trial design, safety monitoring, and follow-up protocols that sponsors must now meet, creating a clearer but more demanding pathway to approval than previously expected.
• Clinical Infrastructure Development: Healthcare systems need to invest in training facilitators, coaches, and practitioners who can deliver the intensive monitoring and therapeutic support that psychedelic-assisted treatments require, addressing the current shortage of qualified personnel.
• International Alignment: The European College of Neuropsychopharmacology is launching a free online course on psychedelic research covering neurobiology, clinical protocols, trial design, and safety, signaling that mainstreaming of this field in Europe may precede or accelerate US adoption.

The field is expanding beyond depression into more challenging territory. Robin Carhart-Harris, one of the most rigorous psychedelic researchers, recently completed a trial of psilocybin therapy for anorexia nervosa, a psychiatric disorder with one of the highest mortality rates. Carhart-Harris described the trial as possibly the hardest work of his career, signaling both the promise and the cost of expanding psychedelic interventions beyond depression into psychiatry's most intractable failures.

"Hard to emphasize enough the challenge of treating anorexia. Was this our hardest trial? Maybe," stated Robin Carhart-Harris, referring to his team's psilocybin research in anorexia nervosa.

Robin Carhart-Harris, Psychedelic Researcher

Meanwhile, other psychedelic molecules are advancing in parallel. Definium Therapeutics released Phase 3 data on DT120, a sublingual LSD formulation, showing clinically meaningful improvement on depression rating scales at six weeks in major depressive disorder. The sublingual delivery format produced discharge-ready patients at five to six hours, attributed in part to LSD's faster absorption through the mouth reducing the tail of the experience. Two molecules, two delivery formats, and two positive late-stage datasets within the same month demonstrate that the FDA is now looking at a field presenting evidence rather than asking for credibility.

The convergence of positive trial data, FDA guidance, and international institutional support signals genuine momentum. Yet practitioners and facilitators should not assume the system is ready to route demand responsibly. Approval creates opportunity, but infrastructure, training, and access remain the true measure of whether psilocybin therapy will reach the patients who need it most.